Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Subjects (Part I), and After Multiple Dose Regimens in Subjects With Chronic Hepatitis B (Part II)

NCT02662712 is registered in ClinicalTrials.gov with Janssen Sciences Ireland UC as lead sponsor.

NCT NCT02662712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02662712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Subjects (Part I), and After Multiple Dose Regimens in Subjects With Chronic Hepatitis B (Part II)
Lead sponsor
Janssen Sciences Ireland UC
Phase
Phase 1
Overall status
Completed
Start date
December 17, 2015
Completion date
June 29, 2018
Enrollment
87 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, hepatitis, chronic